# First Tracks Biotherapeutics Inc. (TRAX)

Source: https://www.quantisnow.com/company/TRAX
Generated: 2026-11-17T17:12:32.511Z

- Ticker: TRAX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0002091349

## Latest TRAX news and filings

- 2026-11-12 14:09 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-first-tracks-biotherapeutics-inc-6786897)
- 2026-11-06 14:45 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-first-tracks-biotherapeutics-6778319)
- 2026-11-04 21:09 UTC [SEC Form 424B3] [SEC Form 424B3 filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-first-tracks-biotherapeutics-inc-6772602)
- 2026-11-04 21:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-first-tracks-biotherapeutics-inc-6772430)
- 2026-11-03 23:02 UTC [SEC Form 4] [Chief Financial Officer Tamboli Ajim was granted 42,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-tamboli-ajim-was-granted-42500-shares-sec-6770676)
- 2026-11-03 23:01 UTC [SEC Form 4] [President, CEO Faga Daniel was granted 136,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-faga-daniel-was-granted-136000-shares-sec-form-6770675)
- 2026-11-03 23:00 UTC [SEC Form 4] [Chief Business Officer Stone Benjamin was granted 42,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-stone-benjamin-was-granted-42500-shares-sec-6770672)
- 2026-11-03 23:00 UTC [SEC Form 4] [Chief Medical Officer Lizzul Paul F. was granted 42,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-lizzul-paul-f-was-granted-42500-shares-6770667)
- 2026-11-03 21:24 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-first-tracks-biotherapeutics-inc-6769994)
- 2026-11-03 21:18 UTC [SEC Form 8-K] [First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-inc-filed-sec-form-8-k-results-of-6769912)
- 2026-11-03 21:15 UTC [Conference Announcement] [First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-announces-participation-in-upcoming-investor-conferences-6769762)
- 2026-11-03 21:15 UTC [Earnings] [First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-reports-third-quarter-2026-financial-results-and-6769752)
- 2026-10-30 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-first-tracks-biotherapeutics-inc-6764348)
- 2026-10-27 21:25 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-first-tracks-biotherapeutics-6759913)
- 2026-10-26 11:37 UTC [SEC Form S-1] [SEC Form S-1 filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-first-tracks-biotherapeutics-inc-6756987)
- 2026-10-20 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-first-tracks-biotherapeutics-inc-6752117)
- 2026-10-15 20:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-first-tracks-biotherapeutics-inc-6748206)
- 2026-10-15 12:00 UTC [Public Offering] [First Tracks Biotherapeutics Announces $200 Million Private Placement](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-announces-200-million-private-placement-6747269)
- 2026-10-13 12:32 UTC [SEC Form 8-K] [SEC Form 8-K filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-first-tracks-biotherapeutics-inc-6744388)
- 2026-10-12 11:00 UTC [First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-announces-positive-top-line-results-for-anb033-in-6743432)
- 2026-10-11 20:00 UTC [First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-to-announce-top-line-data-from-cohort-1-6743370)
- 2026-09-30 12:37 UTC [Analyst Coverage Initiated] [Canaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price target](https://www.quantisnow.com/insight/canaccord-genuity-initiated-coverage-on-first-tracks-biotherapeutics-with-a-6730127)
- 2026-09-18 12:28 UTC [Analyst Coverage Initiated] [Evercore ISI initiated coverage on First Tracks Biotherapeutics with a new price target](https://www.quantisnow.com/insight/evercore-isi-initiated-coverage-on-first-tracks-biotherapeutics-with-a-6720109)
- 2026-09-17 20:05 UTC [SEC Form 4] [Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)](https://www.quantisnow.com/insight/director-orwin-john-a-converted-options-into-1300-shares-increasing-6719038)
- 2026-09-16 12:14 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on First Tracks Biotherapeutics with a new price target](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-first-tracks-biotherapeutics-with-a-new-6717001)
- 2026-09-02 20:12 UTC [SEC Form 144] [SEC Form 144 filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-first-tracks-biotherapeutics-inc-6703169)
- 2026-08-26 20:15 UTC [Conference Announcement] [First Tracks Biotherapeutics Announces Participation in September Investor Conferences](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences-6695645)
- 2026-08-18 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Business Officer Stone Benjamin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-business-officer-stone-benjamin-6686517)
- 2026-08-18 20:05 UTC [SEC Form 4] [SEC Form 4 filed by President, CEO Faga Daniel](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-ceo-faga-daniel-6686501)
- 2026-08-18 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Lizzul Paul F.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-lizzul-paul-6686500)
- 2026-08-18 12:39 UTC [Analyst Coverage Initiated] [Wolfe Research initiated coverage on First Tracks Biotherapeutics with a new price target](https://www.quantisnow.com/insight/wolfe-research-initiated-coverage-on-first-tracks-biotherapeutics-with-a-6686037)
- 2026-08-14 20:22 UTC [SEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-first-tracks-biotherapeutics-inc-6683127)
- 2026-08-13 20:09 UTC [SEC Form SCHEDULE 13G filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-first-tracks-biotherapeutics-inc-6680447)
- 2026-08-13 20:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-first-tracks-biotherapeutics-inc-6680300)
- 2026-08-12 20:24 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by First Tracks Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-first-tracks-biotherapeutics-inc-6678134)
- 2026-08-12 20:19 UTC [SEC Form 8-K] [First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-inc-filed-sec-form-8-k-results-of-6678089)
- 2026-08-12 20:15 UTC [First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/first-tracks-biotherapeutics-announces-second-quarter-2026-financial-results-and-6677961)
- 2026-08-07 21:16 UTC [SEC Form 3] [Amendment: SEC Form 3 filed by new insider Lizzul Paul F.](https://www.quantisnow.com/insight/amendment-sec-form-3-filed-by-new-insider-lizzul-paul-6672125)
- 2026-08-07 21:12 UTC [SEC Form 3] [Amendment: SEC Form 3 filed by new insider Stone Benjamin](https://www.quantisnow.com/insight/amendment-sec-form-3-filed-by-new-insider-stone-benjamin-6672117)
- 2026-08-07 21:11 UTC [SEC Form 3] [Amendment: SEC Form 3 filed by new insider Faga Daniel](https://www.quantisnow.com/insight/amendment-sec-form-3-filed-by-new-insider-faga-daniel-6672111)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TRAX
- Earnings history: https://www.quantisnow.com/earnings/TRAX
- Dividend history: https://www.quantisnow.com/dividends/TRAX
- Insider transactions: https://www.quantisnow.com/insiders/TRAX
- Options chain: https://www.quantisnow.com/options/TRAX
- SEC 8-K filings only: https://www.quantisnow.com/company/TRAX/8-k
- RSS and alerts for TRAX: https://www.quantisnow.com/docs/rss-feeds.md
